Podcast 26 Jul 2024The first mass-market cell therapy? Listen to our conversation with CEO Greg Kunst about how Aurion’s treatment could be the first mass-market cell therapy available July 26, 2024 Share WhatsApp Twitter Linkedin Email Listen Now Apple Music Spotify More
Podcast 19 Jul 2024Cutting through the AI hype in drug discovery There’s certainly hype around AI, but what can it really do in drug discovery? Listen to our conversation with LabGenius to find out. July 19, 2024 Share WhatsApp Twitter Linkedin Email Listen Now Apple Music Spotify More
Podcast 12 Jul 2024How biotechs are revolutionizing acute on-chronic liver failure? Listen to our conversation with Genfit, a late-stage biopharma tackling acute on-chronic liver failure. July 12, 2024 Share WhatsApp Twitter Linkedin Email Listen Now Apple Music Spotify More
Podcast 5 Jul 2024The radiotherapeutics boom The field of radiotherapeutics is a hot topic currently. Listen to our conversation with three experts in the field. July 5, 2024 Share WhatsApp Twitter Linkedin Email Listen Now Apple Music Spotify More
Podcast 21 Jun 2024How ADCs can deliver death cap mushroom toxins to treat cancer Listen to our conversation with Heidelberg Pharma about its lead amanitin-based ADC product candidate, HDP-101. June 21, 2024 Share WhatsApp Twitter Linkedin Email Listen Now Apple Music Spotify More
Podcast 14 Jun 2024Looking to cure type 1 diabetes with precision medicine Listen to our conversation with Diamyd Medical, working on precision medicine therapies for the prevention and treatment of type 1 diabetes. June 14, 2024 Share WhatsApp Twitter Linkedin Email Listen Now Apple Music Spotify More
Podcast 7 Jun 2024Hope for tomorrow: Developing treatments for rare pediatric diseases On this week’s podcast we are discussing novel treatments of rare pediatric diseases with Dan Williams, CEO, executive director of Synaptix Bio. June 7, 2024 Share WhatsApp Twitter Linkedin Email Listen Now Apple Music Spotify More
Podcast 17 May 2024Isarna Therapeutics revolutionizes ophthalmology with antisense oligonucleotides German-headquartered Isarna Therapeutics is developing a portfolio of antisense therapies targeting an emerging therapeutic field in human biology – transforming growth factor beta (TGF-B) signaling. Precise modulation of TGF-B pathways using antisense therapy may result in safer and more effective treatment options for a broad range of indications. Isarna Therapeutics’s lead compound, ISTH0036, is in […] May 17, 2024 Share WhatsApp Twitter Linkedin Email
Podcast 10 May 2024Cytokinetics’ cardiovascular pipeline beats strong Discover Cytokinetics’ groundbreaking cardiovascular treatments, including heart drug aficamten, in our latest podcast with CEO Robert Blum. May 10, 2024 Share WhatsApp Twitter Linkedin Email
In Depth 26 Apr 2024How to overcome clinical trial challenges How can companies overcome clinical trial challenges? Sheila Rocchio from eClinical Solutions and Gen Li from Phesi explain. April 26, 2024 Share WhatsApp Twitter Linkedin Email
Podcast 19 Apr 2024The biotech investment landscape in 2024 Dive into 2024’s biotech investment strategies with RTW Investments on our podcast. Discover trends shaping the landscape ahead.” April 19, 2024 Share WhatsApp Twitter Linkedin Email
Podcast 12 Apr 2024Redefining chronic pain treatment Explore how Doloromics is reshaping chronic pain treatment using cutting-edge omics technologies. Listen to our podcast to learn more. April 12, 2024 Share WhatsApp Twitter Linkedin Email